← FDA DRUG APPROVALS

FDA ANDA · ANDA040481

DIGOXIN

Sponsor: SANDOZ

APPLICATION
ANDA040481
TYPE
ANDA
ORIGINAL APPROVAL
2003-08-21
LATEST ACTION
2020-07-16
ROUTE
INTRAMUSCULAR, INTRAVENOUS, PARENTERAL, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

DIGOXINPrescription
DIGOXIN 0.25MG/ML · INJECTABLE · INJECTION

Approval history

2020-07-16Labeling · Supplement 15 · standardAP
2020-07-16Labeling · Supplement 16 · standardAP
2016-11-02Labeling · Supplement 8 · standardAP
2016-11-02Labeling · Supplement 12 · standardAP
2012-04-27Labeling · Supplement 5 · standardAP
2010-05-18Labeling · Supplement 4AP
2003-08-21OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →